Psychemedics Corporation (PMD)
Largest Insider Buys in Sector
PMD Stock Price History Chart
PMD Stock Performance
About Psychemedics Corporation
Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States, Brazil, and internationally. The company offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opiates, such as heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, …
Insider Activity of Psychemedics Corporation
Over the last 12 months, insiders at Psychemedics Corporation have bought $0 and sold $0 worth of Psychemedics Corporation stock.
On average, over the past 5 years, insiders at Psychemedics Corporation have bought $62,781 and sold $59,182 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 100 shares for transaction amount of $495 was made by SCHAFFER MICHAEL I (VP of Laboratory Operations) on 2022‑12‑16.
List of Insider Buy and Sell Transactions, Psychemedics Corporation
| 2023-08-17 | Sale | Executive Vice President | 12,700 0.2216% | $4.66 | $59,182 | -38.36% | ||
| 2022-12-16 | VP of Laboratory Operations | 100 0.0018% | $4.95 | $495 | -0.54% | |||
| 2022-04-19 | 11,706 0.2061% | $6.52 | $76,323 | -4.56% | ||||
| 2022-04-07 | 4,000 0.0702% | $6.79 | $27,160 | -8.45% | ||||
| 2022-03-31 | director | 4,589 0.082% | $6.92 | $31,756 | -8.27% | |||
| 2022-03-30 | director | 7,814 0.1394% | $6.88 | $53,760 | -7.97% | |||
| 2022-03-16 | 4,000 0.0692% | $6.51 | $26,040 | -5.35% | ||||
| 2020-12-11 | director | 1,000 0.0184% | $4.95 | $4,950 | +45.38% | |||
| 2020-12-08 | Chairman, CEO & President | 1,000 0.0181% | $5.00 | $5,000 | +41.20% | |||
| 2020-11-18 | VP of Laboratory Operations | 500 0.009% | $4.20 | $2,100 | +66.39% | |||
| 2020-11-13 | director | 2,000 0.0341% | $3.92 | $7,840 | +68.44% | |||
| 2020-11-13 | director | 2,000 0.0347% | $3.99 | $7,980 | +68.44% | |||
| 2020-11-12 | Chairman, CEO & President | 2,000 0.0366% | $3.86 | $7,720 | +83.33% | |||
| 2019-06-14 | Sale | VP of Laboratory Operations | 3,900 0.0681% | $9.61 | $37,479 | -7.75% | ||
| 2019-06-14 | Chairman, CEO & President | 1,000 0.0181% | $9.99 | $9,990 | -7.75% | |||
| 2019-06-13 | Sale | VP of Laboratory Operations | 2,631 0.0478% | $9.82 | $25,836 | -5.89% | ||
| 2019-06-12 | Sale | VP of Laboratory Operations | 2,800 0.0507% | $9.84 | $27,552 | -6.49% | ||
| 2019-06-05 | Vice President Sales & Mktg | 500 0.0091% | $9.90 | $4,951 | -6.02% | |||
| 2019-03-12 | Sale | VP - Finance | 1,412 0.0254% | $15.06 | $21,265 | -34.81% | ||
| 2019-03-11 | Sale | VP - Finance | 15,290 0.1389% | $7.55 | $115,516 | -34.33% |
Insider Historical Profitability
| Kamin Peter | 216778 3.6777% | $2.34 | 5 | 0 | <0.0001% | |
| KUBACKI RAYMOND C JR | Chairman, CEO & President | 214374 3.6369% | $2.34 | 7 | 4 | +38.08% |
| WEINERT FRED J | director | 111381 1.8896% | $2.34 | 2 | 7 | +56.91% |
| CONNICK HARRY F SR | director | 41362 0.7017% | $2.34 | 5 | 0 | +60.05% |
| SCHAFFER MICHAEL I | VP of Laboratory Operations | 37201 0.6311% | $2.34 | 3 | 10 | +47.74% |
Institutional Investor Ownership
| 22Nw Fund Lp | $804,045.00 | 4.73 | 274,418 | 0% | +$0 | 0.04 | |
| Renaissance Technologies | $761,000.00 | 4.48 | 259,863 | -2.15% | -$16,692.26 | <0.01 | |
| The Vanguard Group | $736,259.00 | 4.33 | 251,283 | 0% | +$0 | <0.0001 | |
| RBF Capital, LLC | $416,476.00 | 2.45 | 142,142 | 0% | +$0 | 0.02 | |
| BlackRock | $224,872.00 | 1.32 | 76,748 | -0.67% | -$1,520.67 | <0.0001 |